Russian Pharmaceutical Industry Leader
Prospects in the fight against tuberculosis
Prospects in the fight against tuberculosis
Pharmasyntez became a Platinum Sponsor of the All-Russia Scientific and Practical Conference “Tuberculosis and Modern Infections: New Challenges and Prospects”

On December 7-9th, a conference of phthisiatricians dedicated to the memory of M.I. Perelman, academician of the Russian Academy of Medical Sciences, took place in Moscow. The program included a Symposium “Problems associated with tuberculosis in combination with other infectious diseases and possible solutions” with the support of Pharmasyntez. The moderators of the symposium were Valentina Vyacheslavovna Tinkova and Alexander Mikhailovich Panteleev, leading TB specialists. The symposium was devoted to the problems of comorbidity in patients with tuberculosis. The issues discussed were of great relevance for phthisiatricians and led to a lively discussion among the audience.

Elena Sergeevna Ershova, a phthisiatrician from Khanty-Mansiysk, made a report on “Efficacy and safety of combination tuberculosis chemotherapy with Perchlozone in patients with comorbid pathology”. In her report, Elena Ershova gave practical recommendations for practical health care: an algorithm for the assessment of adverse events and case management with thioureidoimino methyl pyridinium perchlorate prescribed.

Innovative anti-tuberculosis drug Perchlozone developed by Pharmasyntez together with the A.E. Favorsky Institute of Chemistry, has been available since 2013. The drug is included in the clinical guidelines ‘Tuberculosis in adults”, 2022 for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis. Since 2015, Perchlozone has officially been included in the list of vital and essential drugs for human use*. This drug case has become a vivid example of interaction between science and business.

Innovative drug PERCHLOZONE is included in the list of vital and essential drugs as of 2015 (